Filtrar

Publicações

Update 2011: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Abstract

OBJECTIVE: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy. METHODS: Several databases were searched, including MEDLINE, ...

Intermittent Versus Continuous Chemotherapy for First-Line Treatment of Unresectable Metastatic Colorectal Cancer (CCRm): Systematic Review and Meta-Analysis

Keywords

Intermittent therapy; continuous therapy; colo-rectal neoplasm; chemotherapy; Systematic Review; meta-Analysis; 

How to cite this article

Botrel, T. E. A., et al. (2011). "Intermittent Versus Continuous Chemotherapy for First-Line Treatment of ...

Cystectomy for locally advanced (pT3-pT4 NX or pTX N1-N3) and metastatic bladder cancer

Keywords

Bladder cancer; localized disease; metastatic; metastasis; cystectomy; 

How to cite this article

Bretas, F. F., et al. (2011). Cystectomy for locally advanced (pT3-pT4 NX or pTX N1-N3) and metastatic bladder cancer. 24th Meeting of the Brazilian Committee of ...

Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil

Abstract

OBJECTIVES: Single-size vials of drugs may be a source of waste and increase in treatment costs. Bortezomib, indicated for multiple myeloma (MM) treatment, is available in 3.5-mg vials, a quantity higher than the average dose commonly prescribed. This analysis aimed to demonstrate, through real-world data, which would be the optimal vial presentation ...

Budgetary Impact of Adoption of Erlotinib for Lung Cancer in the Private Health Insurance Market in Brazil: A Real World Data Analysis

Abstract

OBJECTIVES: In Brazil, health insurance plans (HI) must pay for anticancer intra- venous (IV) chemotherapy (CHEMO) but not for those taken by mouth (PO). Erlotinib (E) is a PO CHEMO used to treat lung cancer 2nd or 3rd line. Our aim was to establish the budgetary impact of the adoption of E, when compared to the IV competitors docetaxel (D) and ...

Capecitabine for the Treatment of Colorectal Cancer in Private Health System in Brazil: A Budgetary Impact Analysis Based on Real World Data

Abstract

OBJECTIVES: Capecitabine (C) is approved in Brazil to treat colorectal cancer CRC, and can replace the combination of 5fluorouracl (5FU) and folinic acid (FA) in many chemotherapy (CHEMO) combination. There are restrictions to their use in the private sector in Brazil, as oral (PO) CHEMO is not covered by health ...

Capecitabine for the Treatment of Breast Cancer in Private Health System in Brazil: Cost analysis Based on Real World Data

Abstract

OBJECTIVES: Capecitabine (C) is approved in Brazil for the treatment of breast cancer (BC), 2nd or subsequent lines. In the private sector, it’s not often used, due to the fact that health insurance plans (HI) do not offer coverage for oral (PO) chemotherapy (CHEMO), only for intravenous (IV). Our aim was to determine ...

Cost of the treatment of myelodisplastic syndrome in Brazil

Abstract

INTRODUCTION: Myelodysplastic syndrome is an incurable and rare hematological disease that affects the production of blood cells. One aim of treatment is to maintain the blood-cell count to near-normal levels. This is mainly achieved with hematopoietic- growth factors and transfusions. Our objective was to determine the cost ...

Cost of Outpatient Endoscopic Capsule (EC) Procedure in Brazil: A Study from a Payer's Perspective

Abstract

OBJECTIVES: There is no published study about the direct costs linked to the pro- cedure of the EC in Brazil. Our aim was to determine a base price of a single procedure of EC. METHODS: Based on a micro cost approach, we first determined the individual items that compose an EC procedure. Then we conducted a market price ...

Economic evaluation of second line treatment of non-small cell lung cancer under the Brazilian private healthcare system perspective

Keywords

Non-small cell lung cancer; private health system; health insurance companies; 

How to cite this article

Marques, M., et al. (2011). "Economic evaluation of second line treatment of non-small cell lung cancer under the ...